These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21052960)

  • 1. Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN.
    Lichtin AE
    Cancer Treat Res; 2011; 157():239-48. PubMed ID: 21052960
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.
    Gascón P; Ludwig H
    Eur J Cancer; 2005 Dec; 41(18):2789-91. PubMed ID: 16253500
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized controlled trials of the erythroid-stimulating agents in cancer patients.
    Glaspy JA
    Cancer Treat Res; 2011; 157():195-215. PubMed ID: 21052958
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report on epoetin use in oncology is precursor to guidelines.
    Levenson D
    Rep Med Guidel Outcomes Res; 2001 May; 12(11):8-9. PubMed ID: 12148526
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines for Epo use in children with cancer.
    Feusner J
    Pediatr Blood Cancer; 2009 Sep; 53(3):308-9. PubMed ID: 19544377
    [No Abstract]   [Full Text] [Related]  

  • 8. Committee releases new guidelines on the use of erythropoiesis-stimulating agents.
    McBride D
    ONS Connect; 2011 Feb; 26(2):19. PubMed ID: 21388023
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
    Djulbegovic B
    Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in anemia management.
    Brown C
    ONS Connect; 2007; 22(8 Suppl):7-8. PubMed ID: 17824542
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa: future directions and future research.
    Ludwig H; Hudis CA; Goss G; Leyland-Jones B
    Oncologist; 2004; 9 Suppl 5():70-3. PubMed ID: 15591424
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
    Spaëth D
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical guidelines for the treatment of cancer-related anemia.
    Koeller JM
    Pharmacotherapy; 1998; 18(1):156-69. PubMed ID: 9469689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anemia: guidelines comparison].
    Del Vecchio L
    G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E; Dimopoulos MA; Zervas K; Terpos E
    Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding the magic formula for ESA use.
    Neumann ME
    Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
    [No Abstract]   [Full Text] [Related]  

  • 20. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure, part III.2: treatment of anaemia with iron.
    Vaage-Nilsen O
    Nephrol Dial Transplant; 2005 Jul; 20(7):1512-3; author reply 1513-4. PubMed ID: 15967789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.